Welcome to our dedicated page for Ge Healthcare Technologies news (Ticker: GEHC), a resource for investors and traders seeking the latest updates and insights on Ge Healthcare Technologies stock.
GE HealthCare Technologies Inc. (Nasdaq: GEHC) is a global healthcare solutions provider focused on medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services, and data analytics. This news page aggregates company announcements, press releases, and other updates related to GE HealthCare’s business activities and capital markets disclosures.
Visitors can find news about GE HealthCare’s collaborations with health systems, governments, and academic institutions, such as agreements to supply advanced CT scanners under national programs, multi-year care alliances with medical centers, and research initiatives in radiation therapy and oncology. The company also issues news on product and technology developments, including imaging systems, AI-powered reconstruction tools, radiology workflow software, and other innovations that it associates with advancing precision care.
GE HealthCare’s news flow includes corporate and investor-focused items as well. Examples include announcements of upcoming earnings releases, participation in healthcare and investor conferences, and responses to shareholder-related matters such as unsolicited mini-tender offers. These communications provide context on how the company presents its strategy, financing activities, and interactions with the capital markets.
Because GE HealthCare emphasizes integrated solutions across Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics, many news items highlight how these businesses work together in specific projects or collaborations. Readers can expect coverage of topics such as AI-enabled imaging, diagnostic access initiatives, training and innovation hubs, and alliances aimed at supporting more efficient and precise care. Investors and observers who follow GEHC news can use this page as a centralized view of the company’s publicly released information and developments over time.
GE HealthCare (GEHC) has unveiled three new deep learning image processing solutions at RSNA 2024: Sonic DL for 3D, Clarify DL, and TrueFidelity DL. These innovations aim to enhance image quality and reduce scan times in medical imaging.
Key highlights include Sonic DL for 3D, which can reduce MRI scan times by up to 86%, Clarify DL for enhanced bone SPECT image quality with 98% better image resolution in clinical evaluations, and TrueFidelity DL for improved cardiac CT imaging.
These solutions join GE HealthCare's existing Effortless Recon DL portfolio, addressing the growing need for improved diagnostic imaging, particularly important as the U.S. expects over two million new cancer cases in 2024.
GE HealthCare (GEHC) showcases its commitment to sustainability at RSNA 2024, highlighting progress in reducing environmental impact while advancing patient care. The company achieved a 13% reduction in greenhouse gas emissions in 2023 and recovered 7,375 imaging machines, resulting in over 15 million pounds of reused material.
Key sustainable innovations include the CT motion syringeless injector, which reduced plastic waste by 84.6% at UW-Madison, and energy-efficient systems like Revolution Apex with Energy Saving Mode 2.0, cutting power consumption by up to 80%. The company also introduced a manganese-based MRI contrast agent as an alternative to gadolinium, addressing environmental concerns.
GE HealthCare (GEHC) has submitted a 510(k) application to the FDA for CleaRecon DL, an AI-based technology designed to enhance cone-beam computed tomography (CBCT) image quality in interventional procedures. The technology aims to remove image streaks and improve image interpretation confidence. To be available on Allia™ Image-Guided Solutions Systems, it represents GE HealthCare's commitment to advancing CBCT adoption. Additionally, the company is introducing OnWatch Predict, a predictive monitoring system for interventional image-guided systems designed to forecast component failures and reduce unplanned downtime.
GE HealthCare (GEHC) has agreed to acquire the remaining 50% stake in Nihon Medi-Physics (NMP) from Sumitomo Chemical, aiming to assume full ownership of the Japanese radiopharmaceutical company. NMP, which generated revenues of 28.2B JPY (~$183M) in 2023, specializes in developing and manufacturing radiopharmaceuticals for SPECT and PET molecular imaging procedures. The company operates 13 manufacturing facilities and focuses on research and development of radiotracers and theranostics. The transaction, expected to close in early 2025 subject to regulatory approvals, will strengthen GE HealthCare's Pharmaceutical Diagnostics segment and enhance patient access to next-generation radiopharmaceuticals in Japan and Asian markets.
GE HealthCare has unveiled Sonic DL for 3D, expanding its MRI deep learning capabilities. The technology enables up to 86% faster scans and enhanced resolution for brain, spine, orthopedic, and body imaging. Building on the success of AIR Recon DL, which has helped over 34 million patients, Sonic DL provides up to 12x scan acceleration while maintaining diagnostic quality. When combined with AIR Recon DL's noise reduction technology, it can enhance image resolution by up to 55%. The solution aims to address healthcare burnout issues while improving workflow efficiency and patient comfort through faster, high-quality imaging for the majority of MR exams.
GE HealthCare will showcase over 40 innovations at RSNA 2024, including AI-enabled technologies focused on optimizing patient care and operational efficiency. The company is introducing several key solutions including Clarify DL for bone image reconstruction, nCommand Lite for remote collaboration, and enhanced True PACS with AI integration. Notable launches include CareIntellect for Oncology, a cloud-first application using generative AI for patient data management, and new theranostics solutions including MINItrace Magni cyclotron and Omni Legend with 21 cm configuration. These innovations reflect GE HealthCare's increased R&D investment since 2022 and address growing challenges in radiology.
GE HealthCare has unveiled the new Pristina Via mammography system at RSNA 2024, designed to enhance breast screening efficiency amid growing technologist shortages. The system features zero-click acquisition, faster image-to-image cycle time, and vendor-neutral prior image comparison.
Developed through extensive collaboration with technologists, including 250 interviews and observations, the system addresses the challenge of increasing vacancy rates (18% in 2024) while maintaining steady mammogram demand. Pristina Via offers the lowest radiation dose among major mammography systems and demonstrates 99% uptime under service contracts.
GE HealthCare (Nasdaq: GEHC) has announced its management team's participation in two major upcoming investor conferences. The first presentation will be at the Nasdaq Investor Conference in London on December 10, 2024, at 11:00 am GMT. The second presentation will take place at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2025, at 4:15 pm CT. Both events will be accessible via webcast through GE HealthCare's investor relations website.
GE HealthCare has enhanced its OEC 3D mobile CBCT C-arm portfolio with new features for endoscopic bronchoscopy procedures. The key additions include the OEC 3D Lung Suite, which offers augmented fluoroscopy overlay and adjustable motorized 3D scanning, and expanded OEC Open interface compatibility with Intuitive's Ion® Endoluminal Robotic Bronchoscopy System. These innovations aim to improve visualization of airways and streamline workflow during bronchoscopy procedures, helping clinicians better diagnose and biopsy lung lesions despite challenges like CT to body divergence.
GE HealthCare hosted its 2024 Investor Day at Nasdaq MarketSite, highlighting its precision care strategy and financial progress. The company announced a 17% increase in quarterly dividend to $0.035 per share. GE HealthCare reiterated its 2024 outlook with organic revenue growth of 1-2% and presented medium-term targets for 2026-2028, including 4-6% organic revenue growth and high-teens to 20%+ adjusted EBIT margin. The company emphasized its focus on innovation, AI strategy, and radiopharmaceutical growth opportunities across its segments.